Spoken Alpha
Tempest Therapeutics, Inc.
Tempest Therapeutics develops cell therapy and small molecule cancer treatments. The company's lead program, TPST-2003, is a dual-targeting CAR-T therapy in clinical trials for relapsed/refractory multiple myeloma, while amezalpat, a small molecule in Phase 3-ready status, targets hepatocellular carcinoma.
Tempest Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $18.7M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add TPST, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TPST.
$ curl https://api.spokenalpha.com/v1/companies/TPSTFAQ
Spoken Alpha indexes TPST's earnings call transcripts at https://spokenalpha.com/companies/TPST. Each call links to attributed speakers and parsed analyst Q&A. Tempest Therapeutics, Inc.'s own investor relations page is at https://ir.tempesttx.com/.
Tempest Therapeutics, Inc. (TPST) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-0.35 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-12 | $-0.34 | $-0.30 | -13.3% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-14 | $-0.50 | $-0.28 | -80.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-29 | $-0.62 | $-0.62 | 0.0% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-0.79 | $-3.27 | +75.8% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-2.07 | $-3.23 | +35.9% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-3.16 | $-3.29 | +4.0% | $486.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-16 | $-0.31 | $-0.24 | -26.5% | $486.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-5.33 | $-4.58 | -16.4% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-5.46 | $-5.33 | -2.4% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-4.68 | $-4.94 | +5.3% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-18 | $-0.38 | $-0.39 | +2.6% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-6.24 | $-7.19 | +13.2% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-7.02 | $-7.54 | +6.9% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $-7.15 | $-8.54 | +16.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-21 | $-0.63 | $-0.76 | +17.1% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-8.58 | $-9.88 | +13.2% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-10.27 | $-12.00 | +14.4% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-12 | $-1.18 | $-1.12 | -5.4% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-28 | $-7.93 | $-16.03 | +50.5% | $0 | — | — | EODHD |
Source: EODHD. TPST reported actuals as published; sparse fields render as —.